Jonathan Aschoff – Roth Capital

Roth Capital

A Roth Capital analyst with 13 tracked ratings across 13 distinct tickers has a 42.9% success rate on the captured sample, covering both identified sources.

Aggregated from multiple market-data sources

Total ratings

Tickers covered

Sources

Aggregated

Latest rating

11 months ago

2025-07-09 00:00:00+00

Track record

Aggregated

43% success rate

Bullish: 0
Hold: 1
Bearish: 0

Aggregated

Not available

Bullish: 5
Hold: 0
Bearish: 0

Recent ratings

Ticker	Date	Rating	Price target	Source
OTRKONTRAK INC	2025-07-09	unknown	$3.00	Aggregated
BRTX	2022-12-07	buy	$15.00	Aggregated
BRTXBIORESTORATIVE THERAPIES INC	2022-12-07	unknown	$15.00	Aggregated
HSDT	2022-08-23	buy	$5.00	Aggregated
HSDTHELIUS MEDICAL TECHNOLOGIES INC - ORDINARY SHARES - CLASS A	2022-08-23	unknown	$5.00	Aggregated
OCGNOCUGEN INC	2022-06-15	unknown	$8.00	Aggregated
CELZ	2022-02-25	buy	$10.00	Aggregated
CELZCREATIVE MEDICAL TECHNOLOGY HOLDINGS INC	2022-02-25	unknown	$10.00	Aggregated
REVB	2022-02-17	buy	$12.00	Aggregated
REVBREVELATION BIOSCIENCES INC	2022-02-17	unknown	$12.00	Aggregated
BFRIBIOFRONTERA INC	2021-11-24	unknown	$20.00	Aggregated
SEELSEELOS THERAPEUTICS INC	2021-08-10	hold	$2.50	Aggregated
APVO	2021-05-28	buy	$50.00	Aggregated

Tickers covered(13)

Ticker	Ratings	Last rating	Sources
OTRKONTRAK INC	1	2025-07-09	Aggregated
BRTX	1	2022-12-07	Aggregated
BRTXBIORESTORATIVE THERAPIES INC	1	2022-12-07	Aggregated
HSDT	1	2022-08-23	Aggregated
HSDTHELIUS MEDICAL TECHNOLOGIES INC - ORDINARY SHARES - CLASS A	1	2022-08-23	Aggregated
OCGNOCUGEN INC	1	2022-06-15	Aggregated
CELZ	1	2022-02-25	Aggregated
CELZCREATIVE MEDICAL TECHNOLOGY HOLDINGS INC	1	2022-02-25	Aggregated
REVB	1	2022-02-17	Aggregated
REVBREVELATION BIOSCIENCES INC	1	2022-02-17	Aggregated
BFRIBIOFRONTERA INC	1	2021-11-24	Aggregated
SEELSEELOS THERAPEUTICS INC	1	2021-08-10	Aggregated
APVO	1	2021-05-28	Aggregated

Methodology differs by source. Track records are aggregated from multiple sources; scoring methodology and scales differ by source and values are not directly comparable. Coverage is sourced from publicly-aggregated analyst activity. Past performance does not guarantee future results. Not investment advice.